MX2017004764A - Formulacion de polvo seco. - Google Patents
Formulacion de polvo seco.Info
- Publication number
- MX2017004764A MX2017004764A MX2017004764A MX2017004764A MX2017004764A MX 2017004764 A MX2017004764 A MX 2017004764A MX 2017004764 A MX2017004764 A MX 2017004764A MX 2017004764 A MX2017004764 A MX 2017004764A MX 2017004764 A MX2017004764 A MX 2017004764A
- Authority
- MX
- Mexico
- Prior art keywords
- dry powder
- powder formulation
- inhaler
- heating
- wrapper
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención proporciona un proceso para preparar una formulación farmacéutica de polvo seco inhalable que comprende la etapa de calentar una envoltura sellada que contiene un desecante y un inhalador o una cápsula, el inhalador o cápsula que contiene, además, una formulación de polvo seco que comprende un ingrediente farmacéutico activo inhalable y un portador, en el que la envoltura forma una barrera a la entrada de humedad y en donde el calentamiento de la envoltura sellada y su contenido se lleva a cabo a una temperatura de 30-50 °C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462064690P | 2014-10-16 | 2014-10-16 | |
PCT/US2015/055919 WO2016061448A1 (en) | 2014-10-16 | 2015-10-16 | Dry powder formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017004764A true MX2017004764A (es) | 2017-07-27 |
Family
ID=54427855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004764A MX2017004764A (es) | 2014-10-16 | 2015-10-16 | Formulacion de polvo seco. |
Country Status (15)
Country | Link |
---|---|
US (1) | US9980904B2 (es) |
EP (1) | EP3206668A1 (es) |
JP (1) | JP6653324B2 (es) |
KR (1) | KR20170068571A (es) |
CN (1) | CN107106514A (es) |
AR (1) | AR102305A1 (es) |
AU (1) | AU2015331915A1 (es) |
BR (1) | BR112017007587A2 (es) |
CA (1) | CA2963146A1 (es) |
CO (1) | CO2017004787A2 (es) |
EA (1) | EA201790833A1 (es) |
IL (1) | IL251665A0 (es) |
MX (1) | MX2017004764A (es) |
PE (1) | PE20170690A1 (es) |
WO (1) | WO2016061448A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015331912A1 (en) * | 2014-10-16 | 2017-05-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable formulation |
ES2953293T3 (es) | 2018-08-07 | 2023-11-10 | Norton Waterford Ltd | Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación |
KR20230066364A (ko) | 2020-08-14 | 2023-05-15 | 노턴 (워터포드) 리미티드 | 플루티카손 프로피오네이트 및 알부테롤 술페이트의 흡입가능 제제 |
GB202012742D0 (en) * | 2020-08-14 | 2020-09-30 | Norton Waterford Ltd | An inhalable medicament |
US20240050382A1 (en) * | 2022-08-11 | 2024-02-15 | De Motu Cordis Pty Ltd | Inhalable Epinephrine Formulation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9027234D0 (en) | 1990-12-15 | 1991-02-06 | Harris Pharma Ltd | An inhalation device |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
SE0303570L (sv) | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
JP4708369B2 (ja) | 2004-02-24 | 2011-06-22 | マイクロドース セラピューテクス,インコーポレイテッド | 合成ジェットに基づく薬剤投与装置 |
GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
US8196576B2 (en) | 2007-02-28 | 2012-06-12 | Microdose Therapeutx, Inc. | Inhaler |
UY31235A1 (es) | 2007-07-21 | 2009-03-02 | Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente | |
GB0919465D0 (en) | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
-
2015
- 2015-10-16 AR ARP150103366A patent/AR102305A1/es unknown
- 2015-10-16 EP EP15790737.9A patent/EP3206668A1/en not_active Withdrawn
- 2015-10-16 PE PE2017000539A patent/PE20170690A1/es not_active Application Discontinuation
- 2015-10-16 CN CN201580055454.1A patent/CN107106514A/zh active Pending
- 2015-10-16 JP JP2017519635A patent/JP6653324B2/ja not_active Expired - Fee Related
- 2015-10-16 CA CA2963146A patent/CA2963146A1/en not_active Abandoned
- 2015-10-16 BR BR112017007587A patent/BR112017007587A2/pt not_active Application Discontinuation
- 2015-10-16 KR KR1020177013067A patent/KR20170068571A/ko unknown
- 2015-10-16 US US15/519,447 patent/US9980904B2/en not_active Expired - Fee Related
- 2015-10-16 EA EA201790833A patent/EA201790833A1/ru unknown
- 2015-10-16 AU AU2015331915A patent/AU2015331915A1/en not_active Abandoned
- 2015-10-16 MX MX2017004764A patent/MX2017004764A/es unknown
- 2015-10-16 WO PCT/US2015/055919 patent/WO2016061448A1/en active Application Filing
-
2017
- 2017-04-09 IL IL251665A patent/IL251665A0/en unknown
- 2017-05-12 CO CONC2017/0004787A patent/CO2017004787A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR102305A1 (es) | 2017-02-15 |
CO2017004787A2 (es) | 2017-09-20 |
BR112017007587A2 (pt) | 2018-01-30 |
CA2963146A1 (en) | 2016-04-21 |
AU2015331915A1 (en) | 2017-05-25 |
JP6653324B2 (ja) | 2020-02-26 |
PE20170690A1 (es) | 2017-05-25 |
US9980904B2 (en) | 2018-05-29 |
KR20170068571A (ko) | 2017-06-19 |
WO2016061448A1 (en) | 2016-04-21 |
US20170239177A1 (en) | 2017-08-24 |
IL251665A0 (en) | 2017-06-29 |
CN107106514A (zh) | 2017-08-29 |
EA201790833A1 (ru) | 2017-09-29 |
EP3206668A1 (en) | 2017-08-23 |
JP2017530995A (ja) | 2017-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017004764A (es) | Formulacion de polvo seco. | |
MX2018015699A (es) | Formulaciones de cannabinoide. | |
IL254353B (en) | A vaporizing capsule for the vaporization of an active ingredient | |
PH12016500547A1 (en) | Aerosol-generating system comprising a cylindrical polymeric capsule | |
RS65327B1 (sr) | Supstituisani indazoli, postupak za njihovo dobijanje, farmaceutski preparati, koji ih sadrže, kao i njihova upotreba za proizvodnju lekova | |
PH12016502248A1 (en) | Adenoassociated virus vectors for the treatment of lysosomal storage disorders | |
MX2015013396A (es) | Derivados de quinolinas como nuevos agentes contra el cancer. | |
IL275220A (en) | Oral administration of active drug substances | |
HK1231416A1 (zh) | 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物 | |
CY1124490T1 (el) | Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο | |
EA201791632A1 (ru) | Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат | |
WO2013104892A8 (en) | Application of high dose compounds via inhalation | |
SG11201605868XA (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
EP3600504A4 (en) | DEVICES AND METHODS FOR ADMINISTRATION OF DRY POWDERED MEDICINAL PRODUCTS | |
WO2014121764A3 (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
IL272806B1 (en) | The history of boronic acid, its preparation and pharmaceutical preparations containing it | |
IL272637A (en) | History of benzaimidazole, their preparation and medicines containing them | |
SG11201610636VA (en) | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor | |
EP3400214C0 (en) | DRY POWDER INHALATOR COMPOSITIONS OF 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES | |
IN2014DE00111A (es) | ||
GR1008442B (el) | Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης | |
PT2617451T (pt) | Conjunto para administrar um medicamento e inalador de dose única para a administração de um medicamento em pó que tenha esse conjunto | |
IL262490A (en) | Lomacaptor complexes and their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them | |
IL262489A (en) | Complexes of ivacaptor and its salts and their history, a process for their preparation and pharmaceutical preparations containing them | |
EA201790832A1 (ru) | Ингалируемый состав |